Lanreotide Sun

Lanreotide, the active ingredient in Lanreotide Sun, is a somatostatin analog presented as a subcutaneous formulation for subcutaneous use. It is employed to control excess growth hormone in patients with acromegaly and to manage hormone‑related symptoms of gastro‑intestinal neuroendocrine tumors.

GNH USA supplies Lanreotide Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for injectable medicines and timely delivery to meet global demand.

Lanreotide is a somatostatin analog used in endocrine and neuroendocrine disorders. - Acromegaly: reduces excess growth hormone and IGF‑1 levels, helping control disease activity. - Gastro‑intestinal neuroendocrine tumors: controls hormone secretion and may inhibit tumor progression. - Carcinoid syndrome: alleviates flushing, diarrhea and other hormone‑related symptoms.

Lanreotide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Nausea: transient gastrointestinal upset. - Diarrhea: loose stools that may be watery. - Hyperglycemia: elevated blood glucose levels.

Serious or Rare Side Effects: - Gallbladder disease: formation of biliary sludge or cholecystitis. - Pancreatitis: inflammation of the pancreas, presenting with severe abdominal pain. - Anaphylactic reaction: rare but potentially life‑threatening allergic response.

When using Lanreotide, several precautions should be observed. - Glucose monitoring: check blood sugar regularly as lanreotide can affect glucose metabolism. - Gallbladder assessment: evaluate for gallstones or biliary disease before initiating therapy. - Cardiac evaluation: monitor heart rhythm in patients with known cardiac conditions. - Hepatic function: use with caution in moderate to severe liver impairment. - Hypersensitivity: discontinue if signs of allergic reaction such as rash or swelling appear. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide may interact with other medicines; awareness of potential interactions is important.

Major Interactions (Avoid): - Other somatostatin analogs: additive hormone suppression may cause severe hypoglycemia. - Insulin or oral hypoglycemic agents: risk of unpredictable blood glucose changes. - Cytochrome P450 3A4 inhibitors: may increase lanreotide plasma concentrations.

Moderate Interactions (Monitor Closely): - Antidiabetic drugs: dose adjustments may be needed. - Gallbladder motility agents (e.g., ursodeoxycholic acid): may alter biliary effects. - Diuretics: monitor electrolytes as lanreotide can affect fluid balance.